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Abstract Secretoneurin is a recently characterized neuropep- 
tide present in the primary amino acid sequence of secretogranin 
II. We investigated the proteolytic processing of secretogranin II
by prohormone convertases in vivo in a cellular system using the 
vaccinia virus system. Both PC1 and PC2 can cleave the secreto- 
granin II precursor at sites of pairs of basic amino acids to yield 
intermediate-sized fragments. Other convertases like PACE4, 
PC5 and furin were not active. For the formation of the free 
neuropeptide secretoneurin a different pattern was found. Only 
PC1 but none of the other convertases tested including PC2 were 
capable of generating secretoneurin. Our results demonstrate 
that the prohormone convertases PC1 and PC2 are involved in 
proteolytic processing of secretogranin II. The neuropeptide se- 
cretoneurin can only be generated by PC1 suggesting tissue- 
specific processing of secretogranin II in neurons expressing dif- 
ferent subsets of the prohormone convertases. 
Key words: Chromogranin; Neuroendocrine; Proteolytic 
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1. Introduction 
Secretoneurin s a novel neuropeptide which is generated in 
vivo by proteolytic processing from its precursor secretogranin 
II [1]. Secretogranin II was initially recognized in pituitary slices 
as a protein strongly labeled by sulfate [2] and later shown to 
occur in many endocrine and nervous tissues [3,4]. Together 
with the chromogranins A and B, secretogranin II belongs to 
the group of acidic proteins generally called chromogranins [5]. 
In bovine adrenal chromaffin granules secretogranin II is 
proteolytically processed to smaller peptides [3,4,6] including 
secretoneurin [7]. In the central and peripheral nervous system 
secretoneurin is found in high concentrations in large dense 
core vesicles [7 10]. As first biological effects a dose-dependent 
release of  dopamine from rat striatal slices [11] and a potent 
chemotactic effect towards monocytes [12] have been described 
recently. 
The enzymes involved in the processing of secretogranin II 
have not yet been established. Recently a class of subtilisin-like 
endopeptidases responsible for prohormone processing was 
identified by its relationship to the kexin protease from yeast. 
*Corresponding author. Fax: (43) (512) 507 2868. 
This class of proteases, which were named prohormone conver- 
rases (PC), comprises several members i.e. PCI/PC3, PC2, 
PACE4, PC4, PC5/PC6 and furin (for reviews see [13-15]). We 
and others recently demonstrated the presence of PC 1 and PC2 
in chromaffin granules of the bovine adrenal medulla [16-18]. 
Since members of the PC family are found in chromaffin gran- 
ules together with secretogranin II we tried to answer in the 
present study the following questions. (i) Are members of the 
PC family involved in endoproteolytic processing of secreto- 
granin II? (ii) Which are the main cleavage sites in the secreto- 
granin II precursor? (iii) Is formation of secretoneurin from 
secretogranin II the result of sequential cleavage by multiple 
endopeptidases or is one convertase alone sufficient o generate 
this neuropeptide? 
2. Materials and methods 
2.1. Infection of cells and analys& of extracts 
A fragment (bases 79-2373) of the bovine secretogranin II (SglI) 
cDNA clone [19] containing the entire coding region was subcloned into 
the vaccinia virus (VV) PMJ601 vector into the 5' SmaIlBamHI 3' site. 
For mouse PC1 and mouse PC2, a full-length transcript was subcloned 
into the vaccinia virus vector pVV3 [20]. The recombinant VV: hfurin, 
VV:hPACE4 and VV:mPC5 were prepared from the PMJ 601 vector 
in a similar fashion to PC1 and PC2 [21,22]. 
Pituitary prolactinoma GH4C 1 cells were infected with either 
VV:SgII alone or VV:SglI plus the respective prohormone 
convertases PC1, PC2, PACE4, PC5 or furin for 2 h. After infection, 
the medium was removed from cells by aspiration. Then, 500/.tl of 
distilled water was added to cells followed by a brief sonication step. 
The cell extracts were transferred to Eppendorf vials and boiled imme- 
diately for 10 min. Boiled samples (cell extracts and media) were centri- 
fuged at 14,000 x g for 20 min. The supernatants were subjected to one- 
and two-dimensional immunoblotting as described in detail [23]. 
Briefly, cell extracts (60/~g) and media (130/.tg protein determined 
according to [24]) from infected cells were separated on a 10-17% 
polyacrylamide gradient gel, electrotransferred to nitrocellulose sheets 
(Schleicher and Schiill, Germany, BA83, 0.2/~m) and incubated with 
antibody and radioiodinated Protein A (NEN, USA). The secreted 
proteins in the medium are likely to represent more directly the peptides 
in the secretory granules, in total cell extracts ome peptides retained 
in the Golgi compartment are also included. However, we also analyzed 
cell extracts and the results matched those obtained with media extracts. 
Antisera (AR-16, LF-19, secretoneurin, EL-17 see [7,12] and anti PC1 
[22]) were used at a dilution of 1 : 200. Immunoreactive proteins were 
visualized by autoradiography and quantified using a Fuji BAS 1000 
phosphoimager system. 
2.2. Gel-filtration HPLC 
Extracts from infected ceils and media were applied to a Superose 12 
HR 10130 gel-filtration column (Pharmacia LKB, Sweden) at a flow 
rate of 0.4 ml/min. As column buffer 37.5 mM sodium phosphate, pH 
7.4 containing 37.5 mM NaC1 was used, One minute fractions were 
collected and analyzed by a radioimmunoassay (RIA) as described 
previously in detail [7]. The specific [7] secretoneurin RIA recognized 
the free peptide as well as its precursor secretogranin II equally well. 
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Fig. 1. Schematic drawing of the secretogranin II precursor. The sequence of bovine secretogranin II [19] is presented. The nine proteolytic cleavage 
sites (pairs of basic amino acids) are indicated by numbers on the top. The putative cleavage at these sites by PC1 or PC2 is indicated. Site 1 (indicated 
by 0) is not used for proteolytic cleavage in vivo [7]. The numbers on the bottom represent the positions of peptides flanked by pairs of basic amino 
acids in the secretogranin II precursor. The abbreviations below, i.e. AR16, LF19, TQ33 (= SN; secretoneurin), EL17 and YM22 indicate the first 
and last amino acid of the peptide given in the single letter code plus the number of total amino acids present which were used for generation of
peptide antisera. The bars below represent identified intermediate-sized cleavage products of secretogranin II and their apparent molecular weight 
as obtained from SDS gels (see Figs. 2 and 3). 
3. Results and discussion 
3.1. Proteolytie processing of secretogranin H by the precursor 
convertases (PC's) 
The processing of secretogranin II by the various pro- 
hormone convertases in vivo was investigated by co-expression 
of these components in GH4C1 cells using the vaccinia virus 
expression system. The pituitary prolactinoma cell-line GH4C 1 
contains very little endogenous secretoneurin-IR asdetermined 
by RIA. After infection with a recombinant vaccinia virus ex- 
pressing bovine secretogranin II (VV: SgII) a 100-fold increase 
in immunoreactivity was found (not shown). By immunoblot- 
ting the molecular form of secretogranin II obtained after virus 
infection was further characterized. An antibody directed 
against a peptide (LF19) representing amino acids 133-151 of 
bovine secretogranin II (see Fig. 1) revealed the presence of 
intact secretogranin II (apparent M r on SDS gels: 87,000) and 
a minor band of M r 75,000 (see Fig. 2). No further processing 
products resulting from a putative cleavage by proteases en- 
dogenous to GH4C 1 cells was evident. Co-infection of these 
cells with VV: SgII plus VV: PC1 resulted in a significant prote- 
olysis of secretogranin II. Three additional bands were gener- 
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Fig. 2. Immunoblots with LF 19 antiserum. Media secreted from GH4C 1 co-infected with recombinant vaccinia virus vectors to express ecretogranin 
II and prohormone convertases were separated in one-dimensional SDS polyacrylamide g ls and subjected to immunoblotting with an antiserum 
against the LF19 peptide (see Fig. 1). C, control cells expressing secretogranin II; PC1, PC2 PACE4, PC5, cells expressing the indicated prohormone 
convertases plus secretogranin II; SL, soluble content of bovine chromaffin granules (50 pg). The position of secretogranin II (SglI) and intermediate 
sized-forms plus their respective apparent molecular weight are indicated on the left. The experiments were performed intriplicate, one representative 
sample is given here. 












Fig. 3. Immunoblot with secretoneurin antiserum. Media secreted from 
GH4C ] co-infected with recombinant vaccinia virus vectors to express 
secretogranin II and prohormone convertases were separated in one- 
dimensional SDS polyacrylamide gels and subjected to immunoblotting 
with an antiserum against secretoneurin (see Fig. 1). C, control cells 
expressing secretogranin II; PC1, PC2 cells expressing the indicated 
prohormone convertases plus secretogranin II; SL, soluble content of 
bovine chromaffin granules (50 ¢tg), The position of secretogranin II 
(SgII) and intermediate sized-formes plus their respective apparent 
molecular weight are indicated on the left. 
ated, two bands with apparent M r of 47,500 and 29,500 and one 
major band of M r 21,800 (see Fig. 2). All three bands generated 
by PC1 are endogenously found in the soluble content of chro- 
maffin granules (see Fig. 2) indicating that PCl-induced cleav- 
age of secretogranin II closely resembles that occurring in vivo 
in the adrenal medulla. Co-infection of VV: SgII and VV: PC2 
yielded the 47,500 and 29,500 intermediate-sized bands (Fig. 2). 
The prominent 21,900 band generated by PC1 was not formed 
by PC2. Co-infection with PACE4, PC5 (Fig. 2) or furin (not 
shown) demonstrated that these proteases were not capable of 
cleaving secretogranin II to any significant degree. Using an 
antiserum against secretoneurin a comparable result, i.e. for- 
mation of the 47,500 and 29,500 bands by PC1 and PC2 was 
obtained (see Fig. 3). The prominent band of 21,900 formed by 
PC1 cannot be detected with the secretoneurin antiserum ap- 
parently due to a lack of this peptide in its sequence (see below 
and Fig. 1). A co-expression fPC 1 plus PC2 together with SgII 
did not alter the pattern of cleavage products in comparison to 
PC1 infection alone (not shown). 
By immunoblotting with antisera directed against an N-ter- 
minal peptide (AR16, see Fig. 1) and a peptide located in the 
middle of secretogranin II (EL17) the relative position of the 
intermediate-sized cleavage products was established. The 
47,500 band was labeled with the AR16, LF19, SN but not with 
the EL17 antiserum and is therefore generated by cleavage at 
sites 4 or 5 (for nomenclature see Fig. 1). Due to a lack of 
further specific antisera the exact cleavage position (either site 
4 or 5) could not be further ascertained. The 29,500 band was 
labeled by the AR16, LF19 and SN antiserum and is formed 
by proteolysis at position 3. The 21,900 band cross- reacts with 
the AR 16 and LF 19 antiserum and therefore results from cleav- 
age at position 2. Taken together, these results indicate that 
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Fig. 4. Gel-filtration HPLC analysis of GH4C l cells. GH4C ] cells were infected with VV : SglI (secretogranin II cDNA subcloned into vaccinia virus) 
or VV:SglI plus VV:PC1. The individual fractions were analysed for secretoneurin-IR with a specific RIA. The positions of secretogranin II (SglI) 
and secretoneurin (SN) in the eluate are indicated. The experiments were performed in triplicate, one representative sample is given here. 
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Fig. 5. Two-dimensional immunoblot of bovine chromaffin granule 
membranes. Membrane proteins were separated by two-dimensional 
electrophoresis. After transfer to nitrocellulose proteins were first m- 
munolabeled with an antiserum directed against the N-terminal region 
of PC1 (aPC 1, lower panel) followed by labeling for glycoproteins with 
concanvalin A (Con A, upper panel). The antiserum recognizes two 
molecular forms of PC1 labeled PC1 85 and PC1-70. The spot corre- 
sponding to PC1 85 is barely visible in the lectin blot. DBH, dopamine 
fl-hydroxylase; CPH, carboxypeptidase H; PC2, prohormone conver- 
tase 2 (compare two-dimensional blots in [18] for identification). 
both PC1 and PC2 can cleave the secretogranin II precursor 
protein at sites 3 and 4/5. Site 2 on the other hand is used only 
by PC1 but not by PC2. This is consistent with a recent finding 
that a proline residue at P4 favors the cleavage by PC1 of 
human prorenin at the ProMetLysArg sitel [25] a sequence 
similar to that of site 2 ProPheLysArgl. In the present experi- 
ments a putative cleavage of the secretogranin II precursor at 
sites 7 to 9 was not investigated. In two recent studies, however, 
peptide fragments resulting from cleavage at sites 8 and 9 were 
isolated [26,27]. Thus, one can assume that these sites might 
also be used in vivo by prohormone convertases. 
3.2. Formation of secretoneurin by endopeptidases 
Secretoneurin is a 33 amino acid peptide present i  he pri- 
mary amino acid sequence of secretogranin II [7]. The putative 
generation of secretoneurin by prohormone convertases was 
investigated by gel-filtration HPLC followed by RIA. Media 
from cells infected with VV: SgII contained one peak of secre- 
toneurin-IR corresponding to secretogranin II (Fig. 4). Very 
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little, if any immunoreactivity was found in the fractions corre- 
sponding to intermediate-sized proteins and secretoneurin. I  
contrast, in cells co-infected with VV: SgII plus VV: PC 1 signif- 
icant amounts of secretoneurin (roughly 50%) were detected 
indicating formation of secretoneurin from its precursor secre- 
togranin II by PC1. In cells co-infected with VV:PC2, 
VV: PACE4, VV: PC5 or VV: furin secretoneurin was not 
generated (not shown). These results indicate that PC1 but 
none of the other convertases tested, i.e. PC2, PACE4, PC5 and 
furin, is capable of generating the neuropeptide s cretoneurin 
from its precursor secretogranin II to any significant degree. 
One prerequisite for a generation of secretoneurin byPC1 in 
vivo is the co-localization of both secretogranin II plus PC1 in 
large dense secretory vesicles. For chromaffin granules the 
presence of PC1 as detected by immunoblotting is iven in Fig. 
5. Two main bands of Mr 85,000 and 70,000 are labeled with 
an antiserum directed against he N-terminal region of PC1. 
Previously, using an antiserum directed against the C-terminus 
only the 85 kDa form was detected [18]. Apparently a signifi- 
cant amount of PC1 in chromaffin granules is already proc- 
essed by cleavage of the C-terminal end as established for ATt- 
20 and GH3 cells [21,25,28,29]. Thus, the results presented here, 
i.e. the formation of secretoneurin induced by overexpression 
of secretogranin II plus PC1 with vaccinia virus in a tumor 
cell-line containing large dense secretory vesicles plus the estab- 
lished co-localization of PC1 with secretogranin II in secretory 
vesicles of adrenal medulla, sympathetic splenic nerve and the 
pituitary [17,30,31] suggests that PC 1 is responsible for genera- 
tion of secretoneurin in vivo. The rather unexpected strict de- 
pendence of the secretoneurin formation on PC1 deserves some 
further comments. In the central nervous ystem PC1 and PC2 
are co-localized in various areas but also distinctly expressed 
in others [32]. Thus, in these neurons a differential processing 
of the secretogranin II precursor to small peptides eems possi- 
ble. Neurons expressing PC1 can generate secretoneurin from 
secretogranin II. In neurons expressing PC2 but no PC1 secre- 
togranin II is also processed to smaller fragments but appar- 
ently not to secretoneurin. It is at present not established 
whether any of these other smaller fragments posses a biologi- 
cal activity as it has been established for secretoneurin. 
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